TUESDAY, April 11, 2017 -- Fewer than one in three men screened with the PSA (prostate-specific antigen) test for prostate cancer talked about the risks and benefits of the test with their doctor.
Those findings come as an influential United States Preventive Services Task Force (USPSTF) panel on Tuesday decided to loosen its recommendations on the PSA test. Now, the panel says discussion between a man and his doctor should guide decisions around getting the test.
TUESDAY, April 11, 2017 -- In a significant shift, a key health advisory panel plans to soften its recommendation against prostate-specific antigen (PSA) screening for detecting prostate cancer.
In 2012, the U.S. Preventive Services Task Force recommended that men no longer get their PSA tested. That recommendation was based on evidence that PSA screening resulted in overdiagnosis and unnecessary treatment that could leave men impotent and incontinent.
SATURDAY, March 25, 2017 -- MRI screening might greatly reduce overdiagnosis and overtreatment of prostate cancer in older men, a preliminary study suggests.
Compared to the current screening method, MRI can reduce overdiagnosis of prostate cancer by 50 percent, and unnecessary biopsies by 70 percent in men over 70, Dutch researchers reported Saturday at a conference in England.